Want to see JP:4880 full AI Analyst Report?
Top Page
CellSource Co., Ltd.
(4880)
Select Model
Select Model
Rating:58Neutral
Price Target:
¥320.00
▼(-19.80% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily supported by financial strength (very conservative balance sheet and continued positive cash generation). Offsetting this are weakening profitability and returns, bearish technical positioning (below key moving averages with negative MACD), and a demanding valuation (P/E ~90) with only a modest dividend yield.
Positive Factors
Conservative balance sheet
Minimal debt and a conservative balance sheet provide durable financial resilience for a biotech firm. This lowers insolvency risk, preserves optionality to fund R&D or partnerships, and allows the company to operate through industry cycles without near-term refinancing pressure.
Negative Factors
Deteriorating profitability and returns
A sharp collapse in returns and margins signals structural operating weakness: reduced earnings power limits internal capital generation, undermines reinvestment capacity and investor returns, and suggests the company must fix core profitability drivers to restore durable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Minimal debt and a conservative balance sheet provide durable financial resilience for a biotech firm. This lowers insolvency risk, preserves optionality to fund R&D or partnerships, and allows the company to operate through industry cycles without near-term refinancing pressure.
Read all positive factors
CellSource Co., Ltd. (4880) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.39B
Dividend Yield1.55%
Average Volume (3M)77.65K
Price to Earnings (P/E)90.4
Beta (1Y)0.92
Revenue Growth-7.13%
EPS GrowthN/A
CountryJP
Employees148
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)3.56
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.79
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5
Revenue Forecast (FY)¥3.70B
CellSource Co., Ltd. Business Overview & Revenue Model
Company Description
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan....
How the Company Makes Money
null...
CellSource Co., Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
85
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.67B | 3.71B | 4.36B | 4.51B | 4.27B | 2.92B |
| Gross Profit | 2.11B | 2.09B | 2.36B | 3.16B | 3.05B | 2.06B |
| EBITDA | 469.11M | 371.03M | 282.38M | 1.29B | 1.63B | 1.05B |
| Net Income | 70.68M | 10.66M | 237.94M | 923.14M | 1.02B | 651.40M |
Balance Sheet | ||||||
| Total Assets | 6.98B | 7.11B | 7.17B | 6.89B | 4.60B | 3.37B |
| Cash, Cash Equivalents and Short-Term Investments | 4.79B | 4.71B | 4.32B | 4.78B | 3.12B | 2.41B |
| Total Debt | 25.26M | 56.72M | 77.29M | 97.54M | 0.00 | 1.10M |
| Total Liabilities | 991.71M | 1.10B | 1.13B | 689.49M | 815.72M | 645.58M |
| Stockholders Equity | 5.99B | 6.02B | 6.04B | 6.20B | 3.79B | 2.72B |
Cash Flow | ||||||
| Free Cash Flow | 289.90M | 289.90M | 98.47M | 498.62M | 752.89M | 843.36M |
| Operating Cash Flow | 333.10M | 333.10M | 591.72M | 846.69M | 847.60M | 898.19M |
| Investing Cash Flow | -3.29M | -3.29M | -614.96M | -624.08M | -169.39M | -256.12M |
| Financing Cash Flow | 61.07M | 61.07M | -437.24M | 1.45B | 14.42M | 9.35M |
CellSource Co., Ltd. Technical Analysis
Negative
399.00
Price Trends
320.80
Negative
349.34
Negative
397.87
Negative
Market Momentum
-4.31
Positive
44.70
Neutral
8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4880, the sentiment is Negative. The current price of 399 is above the 20-day moving average (MA) of 326.60, above the 50-day MA of 320.80, and above the 200-day MA of 397.87, indicating a bearish trend. The MACD of -4.31 indicates Positive momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4880.
CellSource Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥6.39B | 90.45 | ― | 1.24% | -7.13% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ¥27.41B | -62.27 | ― | ― | 3.43% | -53.59% | |
49 Neutral | ¥18.68B | -9.94 | ― | ― | ― | 6.10% | |
45 Neutral | ¥12.82B | -20.35 | ― | ― | -25.02% | -697.06% | |
43 Neutral | ¥31.86B | -9.76 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥8.61B | -7.90 | ― | ― | -62.06% | 7.56% |
* General Sector Average
JP:4880
CellSource Co., Ltd.
313.00
-378.06
-54.71%
JP:4593
Healios KK
246.00
-386.00
-61.08%
JP:4599
StemRIM Inc.
303.00
-27.00
-8.18%
JP:4978
ReproCELL Inc.
131.00
-87.00
-39.91%
JP:7774
Japan Tissue Engineering Co., Ltd.
797.00
258.00
47.87%
JP:7776
CellSeed Inc.
228.00
-250.00
-52.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.